Boston Scientific (BSX) stock decreased by 1.72% as a result of concerns related to its significant acquisition of Axonics, which could impact its market performance and investor confidence.

Boston Scientific (BSX) stock decreased by 1

Boston Scientific Corporation (BSX) shares experienced a slight decline of 0.07% after reaching a 52-week high following a strong earnings report, attributed to insider stock sales by executives and market speculation amid the stock's prior gains.

Boston Scientific Corporation (BSX) shares experienced a slight decline of 0

Boston Scientific (BSX) stock rose by 4.46% due to strong market recovery fueled by optimism over global trade developments and sectoral strength, which improved investor sentiment.

Boston Scientific (BSX) stock rose by 4

Boston Scientific (BSX) stock rose 4.46% following a strong second-quarter report and positive full-year guidance.

Boston Scientific (BSX) stock rose 4

Boston Scientific (BSX) stock rose by 4.46% amidst a positive market environment influenced by new trade deals and anticipation of earnings reports from significant tech companies, suggesting optimism about economic growth.

Boston Scientific's (BSX) stock fell by 0.6% last night, potentially due to market anticipation ahead of its upcoming earnings announcement on July 23, 2025, and investor sentiment influenced by historical performance and peer stock reactions.

Boston Scientific's (BSX) stock fell by 0

Boston Scientific (NYSE:BSX) stock rose by 0.14% ahead of its Q2 2025 earnings announcement, attributed to positive analyst expectations for earnings and revenue growth from the company.

Boston Scientific (NYSE:BSX) stock rose by 0

Boston Scientific (BSX) stock rose by 0.14% due to a favorable shift in analyst ratings, with upgrades and positive target price adjustments from multiple investment firms, reflecting strong earnings performance and investor confidence in the company's growth prospects.

Boston Scientific (BSX) stock rose by 0

Boston Scientific (BSX) stock rose by 1.41% last night, reflecting its strong market performance over the past five years, where it outperformed the market with an annualized return of 22.61%, contributing to its substantial market capitalization of $152.21 billion.

Boston Scientific (BSX) stock rose by 1

Boston Scientific (BSX) stock declined by 0.81% due to market reactions following the announcement of FDA labeling expansion for its FARAPULSE Pulsed Field Ablation system, which may have influenced investor sentiment despite positive outlooks from analysts like Goldman Sachs.

Boston Scientific (BSX) stock declined by 0

Boston Scientific (BSX) stock fell by 0.81% despite its positive outlook from analysts following recent FDA approvals and strong clinical trial results due to investors possibly favoring AI stocks with higher growth potential and lower risk.

Boston Scientific (BSX) stock fell by 0

Boston Scientific Corporation's stock (NYSE: BSX) rose by 0.87% following a consensus "Buy" recommendation from 24 brokerages, positive earnings reports that exceeded estimates, and several analysts raising their price targets for the stock.

Boston Scientific Corporation's stock (NYSE: BSX) rose by 0

The article discusses the recent 18% increase in Abbott Laboratories (ABT) stock, contrasting it with the 6% rise in the S&P 500, attributing ABT's strong performance to solid quarterly results, positive forecasts, and compelling operational metrics, although it also notes that the stock appears slightly overpriced compared to the broader market. 

Boston Scientific (BSX) stock's increase may be linked to overall positive sentiment in the healthcare sector, driven by strong performances from competitors like Abbott, alongside specific factors affecting BSX's operational metrics or market positioning.

The article discusses the recent 18% increase in Abbott Laboratories (ABT) stock, contrasting it wit

Boston Scientific (BSX) stock fell by 1.37% recently, largely due to significant insider selling and a decrease in stake by Mutual Advisors LLC, raising concerns among investors about potential future performance.

Boston Scientific (BSX) stock fell by 1

Boston Scientific (BSX) stock fell by 1.37% amid changes in institutional stock positions and news of insider selling, which can indicate potential concerns about the company's stock performance or management's outlook.

Boston Scientific (BSX) stock decreased by 0.47% due to a significant reduction in stake by Golden State Wealth Management LLC, which cut its holdings by 46.6% in the first quarter, indicating potential concerns among investors regarding the stock's future performance.

Boston Scientific (BSX) stock decreased by 0

Boston Scientific (BSX) stock fell by 2.45% amid recent insider selling and mixed analyst ratings despite institutional investments and strong earnings growth. The decline could be attributed to the significant insider stock sales, which may signal a lack of confidence among company executives, alongside market fluctuations affecting investor sentiment.

Boston Scientific (BSX) stock fell by 2

Boston Scientific (BSX) stock rose by 0.83% due to positive analyst ratings and increased institutional investment interest, reflecting confidence in the company's financial performance and growth potential in the medical device sector.

Boston Scientific Corporation (BSX) saw a 1.86% increase in its stock price, driven by strong growth from its Watchman heart implant and the promising potential of its Farapulse treatment for atrial fibrillation, as highlighted in the Parnassus Growth Equity Fund's Q1 2025 investor letter.

Boston Scientific Corporation (BSX) saw a 1

Boston Scientific (BSX) stock increased by 0.28% due to recent institutional investments and positive analyst ratings, reflecting growing confidence in the company's financial performance and future earnings potential.

Boston Scientific (BSX) stock increased by 0

Boston Scientific (BSX) stock rose by 0.28% last night reportedly due to positive analyst upgrades and strong earnings performance that exceeded expectations, indicating investor confidence in the company's growth potential.

Boston Scientific (BSX) stock rose by 1.05% following positive momentum driven by analyst upgrades, strong quarterly earnings that exceeded expectations, and significant interest from institutional investors, with a majority of the stock owned by hedge funds and positive price target revisions from various analysts.

Boston Scientific (BSX) stock fell by 0.35% despite an upgrade to a strong-buy rating by Leerink Partners, possibly due to insider selling and concerns about the overall market sentiment affecting stock performance.

Boston Scientific (BSX) stock experienced a decline of 0.35% due to a notable reduction in institutional ownership, including a 4.9% decrease in shares held by Exchange Traded Concepts LLC, coupled with significant insider selling by executives, including the CEO.

Boston Scientific (BSX) stock experienced a decline of 0

Boston Scientific (BSX) stock decreased by 0.35% following Leerink Partners' estimates of its upcoming earnings per share, despite the firm maintaining a "Strong-Buy" rating; the stock drop may be influenced by broader market factors and profit-taking from investors after recent performance.

Boston Scientific (BSX) stock rose by 0.24% due to an initiation of coverage with an Outperform rating and a $118 price target by Leerink, highlighting positive growth prospects for the company.

Boston Scientific (BSX) stock increased by 0.24% following positive coverage from Leerink Partners, which issued an "outperform" rating and set a price target of $118.00, along with several upgrades from other analysts that boosted target prices and reaffirmed strong buy ratings.

Boston Scientific (BSX) stock rose 1.75% and has gained over 30% in the last year, largely due to successful product launches that have improved sales and profit margins, despite a current valuation that appears high compared to historical metrics and the broader market.

Boston Scientific (BSX) stock rose 1

Boston Scientific (BSX) stock was up 1.2% likely due to positive developments related to the efficacy of intravenous iron therapy with ferric derisomaltose (FDI) for treating heart failure with reduced ejection fraction (HFrEF) and iron deficiency, supporting its benefits for older patients, which could enhance investor confidence in the company's product pipeline.

Boston Scientific (BSX) stock was up 1

Boston Scientific (BSX) stock rose by 1.2% following significant investment increases from institutional investors and positive analyst evaluations, including upgraded price targets and consistent earnings performance above estimates.

Boston Scientific's stock (BSX) rose by 0.06% due to increased institutional investment, with notable stakes being added by several hedge funds, reflecting positive investor sentiment following strong quarterly earnings that exceeded expectations.

Boston Scientific's stock (BSX) rose by 0

Boston Scientific's stock (BSX) increased by 0.06% due to significant institutional investments, positive quarterly earnings performance that exceeded expectations, and multiple upgrades in the company's stock price targets from research firms.

Boston Scientific's stock (BSX) increased by 0

Boston Scientific (BSX) stock fell by 2.01% due to a combination of recent insider selling and overall market fluctuations, despite strong earnings performance reported earlier in the quarter.

Boston Scientific (BSX) stock rose by 0.39% following a strong quarterly earnings report that exceeded analyst expectations, alongside favorable ratings and price target adjustments from several brokerages, indicating positive investor sentiment.

The article discusses a meta-analysis comparing the long-term effectiveness of P2Y12 inhibitor monotherapy versus aspirin monotherapy for patients post-percutaneous coronary intervention (PCI), finding that P2Y12 inhibitors result in lower major adverse cardiac and cerebrovascular events without increasing major bleeding risks. The decline of Boston Scientific (BSX) stock by 0.65% may be attributed to investor reactions to market conditions or regulatory developments affecting medical device manufacturers rather than the specifics of the study presented.

The article discusses a meta-analysis comparing the long-term effectiveness of P2Y12 inhibitor monot

Boston Scientific (BSX) stock fell by 1.04% due to a variety of market factors, despite its strong historical performance of an average annual return of 21.59% over the past 15 years.

Boston Scientific (BSX) stock experienced a small increase of 0.73% last night amid fluctuations, with a current price of $104.20, following a slight recent decline but showing significant growth over the past year. The increase in BSX stock can be attributed to positive market sentiment and strong performance indicators, such as a 39.11% rise over the past year.

Boston Scientific (BSX) stock experienced a small increase of 0

Boston Scientific's stock (BSX) experienced a slight decline of 0.01% despite reaffirmed buy ratings and price target increases from multiple analysts, potentially influenced by recent insider sales of shares, which may signal concerns about future performance.

Boston Scientific's stock (BSX) experienced a slight decline of 0

Boston Scientific's stock fell by 1.56% after the company announced it would stop selling its rival heart-valve replacement systems, which positively impacted the stocks of competitors like Edwards Lifesciences, Medtronic, and Abbott.

Boston Scientific's stock fell by 1

Boston Scientific's stock (BSX) declined by 0.13%, attributed to unusual options trading activity where put options increased significantly, alongside notable insider sell-offs by executives, indicating potential concerns about the stock's future performance.

Boston Scientific's stock (BSX) declined by 0

Boston Scientific (BSX) stock declined by 0.13% amid Citi's revision of MedTech coverage following the announcement of a 90-day U.S.–China tariff de-escalation, which rendered previous guidance uncertain while demonstrating increased sensitivity to stock performance amidst a volatile market environment.

Boston Scientific (BSX) stock rose 1.13% as it was added to the IBD 50 list, reflecting its strong performance and potential for growth. The increase is likely attributed to its recognition on a prominent stock list, indicating investor confidence and positive market sentiment.

Boston Scientific (NYSE: BSX) stock remains unchanged at 0.0% following recent insider sales, including shares sold by Representative Bruce Westerman and other executives, which may have contributed to a lack of investor confidence.

Boston Scientific (NYSE: BSX) stock remains unchanged at 0

Boston Scientific (BSX) stock rose by 0.31% following an upgrade from a "hold" to a "buy" rating by StockNews.com, along with multiple price target increases and optimistic performance reports from various analysts, reflecting strong quarterly earnings and positive market sentiment.

Boston Scientific (BSX) stock rose by 0.55% due to its strong relative strength performance, reaching a 52-week high alongside other stocks like SAP and Howmet Aerospace, suggesting positive market momentum and investor confidence.

Boston Scientific (BSX) stock rose 0.27% after Barclays raised its price target for the company from $118.00 to $125.00, highlighting positive sentiment from multiple research firms that have upgraded their ratings and target prices for the stock.

Boston Scientific (BSX) stock rose 0

Boston Scientific (BSX) stock rose 2.24% after showing strong technical patterns, including a potential double bottom formation and maintaining a high composite rating and impressive industry ranking. 

The stock's increase is likely attributed to investor confidence in its chart patterns, such as the double bottom, coupled with favorable stock ratings that indicate strong potential for growth.

Boston Scientific (BSX) stock rose 2

Boston Scientific (BSX) stock rose by 4.07% as part of a broader positive market sentiment toward medical stocks, which were showing high trading volumes and interest, likely driven by ongoing innovations and developments in the healthcare sector.

Boston Scientific's stock rose 4.07% after the company exceeded first-quarter earnings expectations and increased its sales forecast.

Boston Scientific's stock rose 4

Boston Scientific (BSX) stock rose by 4.07% as it continues to be favored among hedge funds, as indicated in a recent article highlighting the best stocks under $100 to buy.

Boston Scientific (BSX) stock fell by 1.62% ahead of its upcoming quarterly earnings report, which analysts project may not meet investor expectations given the mixed signals from recent insider selling and market sentiment about company forecasts.

Boston Scientific (BSX) stock declined by 0.14% as it is currently undergoing a first-stage consolidation phase, making it a stock worth monitoring as it seeks to regain support levels. The decline may be attributed to this consolidation process, which often involves price fluctuations before establishing a stronger upward trend.

Boston Scientific (BSX) stock decreased by 0.14% due to ongoing concerns in the healthcare sector regarding rising costs and potential impacts of tariffs on production and research, particularly related to its reliance on Chinese manufacturing and contract research organizations.

Boston Scientific (BSX) stock fell by 0.14% after Needham upgraded the stock to Buy from Hold with a price target of $113, citing better-than-expected results in a recent electrophysiologist survey, which suggested diminished competition risks, indicating that the downgrade likely stirred some investor caution leading to the slight decline.

Boston Scientific (BSX) stock was down 0.04% possibly due to its high valuation metrics, including a forward price-to-sales ratio of 7.2 and a premium price reflecting vulnerability amidst recessionary conditions.

Boston Scientific (BSX) stock was down 0

Boston Scientific (BSX) stock rose by 6.76% due to a notable increase in call options trading, with investors showing confidence in the stock following positive earnings results and analysts raising their price targets for the company.

Boston Scientific (BSX) stock rose by 6

Boston Scientific (BSX) stock decreased by 0.98% to $89.78 due to market volatility affecting medical stocks, as evidenced by similar declines in other major healthcare companies like UnitedHealth Group and Eli Lilly, reflecting broader trading trends in the sector.

Boston Scientific (BSX) stock fell by 1.55% in a session marked by a 3.16% drop, driven by mixed short-term performance despite a strong 44.16% increase over the past year.

Boston Scientific (BSX) stock declined by 1.18% due to a lack of momentum as it approached its 50-day moving average resistance level and showed neutral short-term directional bias, suggesting potential bearish trading opportunities.

Boston Scientific (BSX) stock declined by 1

Boston Scientific (BSX) stock rose by 0.36% due to a strong average recommendation of "Buy" from several analysts, positive target price upgrades, and favorable earnings results, indicating optimism about the company’s performance and future growth potential.

Boston Scientific (BSX) stock was down 1.5% due to general market conditions and potential investor concerns about the company's recent performance and outlook.

Boston Scientific (BSX) stock was down 1

Boston Scientific (BSX) stock rose 0.4% last night, approaching a buy point of 107.47 within a flat base pattern, with early entry points at 101.50 and 103, aided by a strong composite rating of 99/99.

Boston Scientific's (BSX) stock rose by 0.4% due to significant increases in institutional investments, including a 40.2% stake increase by Proficio Capital Partners LLC and other hedge funds boosting their holdings, alongside positive analyst ratings and upgraded price targets.

Boston Scientific's (BSX) stock rose by 0

Boston Scientific (BSX) stock rose by 1.48% due to its strong historical performance, having outperformed the market by 9.97% annually over the past five years, resulting in a substantial average annual return of 28.2%.

Boston Scientific (BSX) stock decreased by 1.66% likely due to a combination of insider sales, including significant transactions by company executives, potentially signaling a lack of confidence in the stock's near-term performance, despite overall positive earnings reports and institutional buying interest.

Boston Scientific (BSX) stock rose by 1.06% following positive analyst ratings, including increased price targets and buy ratings from several firms, which contributed to heightened investor confidence.

Boston Scientific (BSX) stock fell by 1.2% despite receiving mostly positive ratings and increased price targets from various analysts due to insider selling activity, which often raises concerns among investors about the company's future prospects.

Boston Scientific (BSX) stock fell by 0.75% following significant insider selling, including a notable sale by EVP Arthur C. Butcher, which may have raised concerns among investors.

BSX

Latest News & Analysis